Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 1, 1999, Pages 85-89

  Miyazaki, Eishi ^a   Miyazaki, Miki ^a   Chen, Jong Min ^a   Chaisson, Richard E ^a,b   Bishai, William R ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TUBERCULOSTATIC AGENT;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0032910406     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.1.85     Document Type: Article

References (27)

1. Aldridge, K. E., and D. S. Ashcraft. 1997. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob. Agents Chemother. 41:709-711.
2. Boswell, F. J., J. M. Andrews, and R. Wise. 1997. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantihiotic effect. Antimicrob. Agents Chemother. 41:1377-1379.
3. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Slandiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
4. Fass, R. J. 1997. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Antimicrob. Agents Chemother. 41:1818-1824.
5. Frieden, T. R., T. Sterling, A. Pablos-Mendez, J. O. Kilburn, G. M. Cauthen, and S. W. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Mod. 328:521-526.
6. Goble, M., M. D. Iseman, L. A. Madsen, D. Waite, L. Ackerson, and C. R. Horsburgh, Jr. 1993. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328:527-532.
7. Goldstein, E. J. C., D. M. Citron, M. Hudspeth, S. H. Gerardo, and C. V. Merriam. 1997. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob. Agents Chemother. 41:1552-1557.
8. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
9. Ji, B., C. Truffot-Pernot, and J. Grosset. 1991. In vitro and in vivo activities of sparfloxacin (AT 4140) against Mycobacterium tuberculosis. Tubercle Lung Dis. 72:181-186.
10. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:2066-2069.
11. Kennedy, N., L. Berger, J. Curram, R. Fox, J. Gutmann, G. M. Kisyombe, F. I. Ngowi, A. R. C. Ramsay, A. O. S. Saruni, N. Sam, G. Tillotson, L. O. Uiso, M. Yates, and S. H. Gillespie. 1996. Randomized controlled trial of drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin. Infect. Dis. 22:827-833.
12. Kohno, S., H. Koga, M. Kaku, S. Maesaki, and K. Hara. 1992. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 102:1815-1818.
13. Lalande, V., C. Trufol-Pernot, A. Paccaly-Moulin, J. Grosset, and B. Ji. 1993. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother. 37:407-413.
14. Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1997. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob. Agents Chemother. 41:607-610.
15. Meinen, J. B., J. T. McClure, and E. Rosin. 1995. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Am. J. Vet. Res. 56:1219-1224.
16. Nakagawa, T., M. Ishigai, M. Kato, N. Hayakawa, H. Kinoshita, T. Okutomi, K. Ohkubo, and A. Ozaki. 1995. Pharmacokinetics of the new fluoroquinolone balofloxacin in mice, rats and dogs. Arzneim.-Forsch. 45:719-722.
17. Pablos-Mendez, A., M. Raviglione, A. Laszlo, N. Binkin, H. Rieder, F. Bustreo, D. L. Cohn, C. S. B. Lambregts-van Weezenbeek, S. J. Kim, P. Chaulet, and P. Nunn. 1998. Global surveillance for antituberculosis-drug resistance, 1994-1997. N. Engl. J. Med. 338:1641-1649.
18. Siddiqi, S. 1992. Radiometrie (BACTEC) tests for slowly growing mycobacteria, p. 5.14.1-5.14.25. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, vol. 1. American Society for Microbiology, Washington, D.C.
19. Sirgel, F. A., F. J. Botha, D. P. Parkin, B. W. Van de Wal, R. Schall, P. R. Donald, and D. A. Mitchison. 1997. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 156:901-905.
20. Small, P. M., G. F. Scheeler, P. C. Goodman, M. A. Sande, R. E. Chaisson, and P. C. Hopewell. 1991. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 324:289-294.
21. Stass, H., A. Dalhoff, D. Kubitza, and U. Schühly. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065.
22. Sullivan, J., M. Woodruf, J. Lettieri, V. Agarwal, G. Krol, and A. Heller. 1997. Pharmacokinetics (PK) and tolerability of the new quinolone BAY 12-8039: 10 days' treatment at 400 mg daily, abstr. P-389, p. 87. In Abstracts of the 8th European Congress of Clinical Microbiology and Infectious Diseases 1997. European Society of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland.
23. Truffot-Pernot, C., B. Ji, and J. Grosset. 1991. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle Lung Dis. 72:57-64.
24. Tsukamura, M. 1985. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL-8280). Am. Rev. Respir. Dis. 131:348-351.
25. Tsukamura, M., E. Nakamura, S. Yoshii, and H. Amano. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL-8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. 131:352-356.
26. Valway, S. E., M. P. Sanchez, T. F. Shinnick, I. Orme, T. Agerton, D. Hoy, J. S. Jones, H. Westmorland, and I. M. Onorato. 1998. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med. 338:633-639.
27. Woodcock, J. M., J. M. Andrews, F. J. Boswell, N. P. Brenwald, and R. Wise. 1997. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:101-106.